Semma Therapeutics, Inc. — Form D/A
Semma Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2019-02-26. The offering totals $119.9M, of which $113.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-02-26
- Form: D/A
- Accession: 0001637931-19-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $119.9M
- Amount sold: $113.9M
- Remaining: $6.0M
- Investors: 20
- Date of first sale: 2017-11-27
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-300037
Issuer
- Name: Semma Therapeutics, Inc.
- CIK: 0001637931
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 450 KENDALL STREET, CAMBRIDGE, MA, 02142
- Phone: 857-529-6430
Officers, directors & promoters (16)
| Name | Role | Location |
|---|
| Daniel Auerbach | Director | South San Francisco, CA |
| Mitchell Finer | Director | Cambridge, MA |
| Mark Fishman | Director | Oakland, CA |
| Todd Foley | Director | South San Francisco, CA |
| Stephen Knight | Director | NEW HAVEN, CT |
| Kevin Raidy | Director | Thousand Oaks, CA |
| William Sahlman | Director | Cambridge, MA |
| Bastiano Sanna | Director | Cambridge, MA |
| Todd Foley | Executive Officer | South San Francisco, CA |
| Bastiano Sanna | Executive Officer | Cambridge, MA |
| Kingsley Taft | Executive Officer | Boston, MA |
| MITCH FINER | Director | WATERTOWN, MA |
| Jim Scopa | Director | South San Francisco, CA |
| Robert Millman | Director | MEDFIELD, MA |
| Robert Millman | Executive Officer | MEDFIELD, MA |
| Elizabeth Stoner | Executive Officer | Cambridge, MA |
Other filings by this issuer (3)
More